+

WO2010005567A3 - Agents de liaison de récepteur notch1 et procédés d'utilisation - Google Patents

Agents de liaison de récepteur notch1 et procédés d'utilisation Download PDF

Info

Publication number
WO2010005567A3
WO2010005567A3 PCT/US2009/003995 US2009003995W WO2010005567A3 WO 2010005567 A3 WO2010005567 A3 WO 2010005567A3 US 2009003995 W US2009003995 W US 2009003995W WO 2010005567 A3 WO2010005567 A3 WO 2010005567A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
receptor binding
binding agents
notch1 receptor
antibody
Prior art date
Application number
PCT/US2009/003995
Other languages
English (en)
Other versions
WO2010005567A2 (fr
Inventor
Austin L. Gurney
Timothy Charles Hoey
Maureen Fitch Bruhns
Fumiko Takada Axelrod
Original Assignee
Oncomed Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DK09794822.8T priority Critical patent/DK2307459T3/da
Priority to MEP-2015-20A priority patent/ME02069B/me
Priority to CN200980126471.4A priority patent/CN102112490B/zh
Priority to BRPI0914004A priority patent/BRPI0914004A2/pt
Priority to PL09794822T priority patent/PL2307459T3/pl
Priority to JP2011517417A priority patent/JP5560271B2/ja
Priority to EA201170158A priority patent/EA026109B1/ru
Priority to MX2011000233A priority patent/MX2011000233A/es
Priority to CA2729602A priority patent/CA2729602A1/fr
Priority to EP09794822.8A priority patent/EP2307459B1/fr
Priority to RS20150120A priority patent/RS53750B1/en
Priority to NZ590127A priority patent/NZ590127A/xx
Priority to AU2009269096A priority patent/AU2009269096B9/en
Priority to US13/003,013 priority patent/US8435513B2/en
Priority to SI200931146T priority patent/SI2307459T1/sl
Application filed by Oncomed Pharmaceuticals, Inc. filed Critical Oncomed Pharmaceuticals, Inc.
Priority to ES09794822.8T priority patent/ES2531541T3/es
Priority to UAA201101442A priority patent/UA101672C2/uk
Publication of WO2010005567A2 publication Critical patent/WO2010005567A2/fr
Publication of WO2010005567A3 publication Critical patent/WO2010005567A3/fr
Priority to IL210222A priority patent/IL210222A/en
Priority to MA33483A priority patent/MA32448B1/fr
Priority to ZA2011/00029A priority patent/ZA201100029B/en
Priority to HK11105234.2A priority patent/HK1151296A1/xx
Priority to US13/797,374 priority patent/US9132189B2/en
Priority to US13/801,613 priority patent/US8945874B2/en
Priority to US13/826,284 priority patent/US8945547B2/en
Priority to US14/577,484 priority patent/US9499613B2/en
Priority to SM201500047T priority patent/SMT201500047B/xx
Priority to HRP20150256AT priority patent/HRP20150256T1/hr
Priority to US15/291,334 priority patent/US20170183405A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/18—Kallidins; Bradykinins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions et des procédés permettant de caractériser, de diagnostiquer et de traiter le cancer, et en particulier des moyens et des procédés pour le diagnostic, la caractérisation, le pronostic et le traitement du cancer et le ciblage spécifique de cellules souches du cancer. On décrit un anticorps se liant spécifiquement à une zone proximale de membrane de liaison hors ligand du domaine extracellulaire d'un récepteur Notch humain et inhibe la croissance tumorale. On décrit en outre un procédé de traitement du cancer qui consiste à administrer une quantité thérapeutiquement efficace d'anticorps se liant spécifiquement à la zone susmentionnée de récepteur Notch humain et inhibe la croissance tumorale.
PCT/US2009/003995 2008-07-08 2009-07-08 Agents de liaison de récepteur notch1 et procédés d'utilisation WO2010005567A2 (fr)

Priority Applications (28)

Application Number Priority Date Filing Date Title
SI200931146T SI2307459T1 (sl) 2008-07-08 2009-07-08 Notch 1 receptor vezavna sredstva in postopki njihove uporabe
CN200980126471.4A CN102112490B (zh) 2008-07-08 2009-07-08 Notch1受体结合剂和其使用方法
BRPI0914004A BRPI0914004A2 (pt) 2008-07-08 2009-07-08 agentes de aglutinação de receptor notch1 e métodos de uso mesmo
PL09794822T PL2307459T3 (pl) 2008-07-08 2009-07-08 Czynniki wiążące receptor Notch1 i sposoby ich stosowania
JP2011517417A JP5560271B2 (ja) 2008-07-08 2009-07-08 Ｎｏｔｃｈ１受容体結合剤およびその使用方法
EA201170158A EA026109B1 (ru) 2008-07-08 2009-07-08 АГЕНТЫ, СВЯЗЫВАЮЩИЕСЯ С РЕЦЕПТОРОМ Notch1, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
MX2011000233A MX2011000233A (es) 2008-07-08 2009-07-08 Agentes de union del receptor notch1 y metodos para su uso.
CA2729602A CA2729602A1 (fr) 2008-07-08 2009-07-08 Agents de liaison de recepteur notch1 et procedes d'utilisation
EP09794822.8A EP2307459B1 (fr) 2008-07-08 2009-07-08 Agents de liaison de récepteur notch1 et procédés d'utilisation
RS20150120A RS53750B1 (en) 2008-07-08 2009-07-08 NOTCH1 RECEPTOR BINDING AGENTS AND APPLICATION PROCEDURES
NZ590127A NZ590127A (en) 2008-07-08 2009-07-08 Notch1 receptor binding agents and methods of use thereof
AU2009269096A AU2009269096B9 (en) 2008-07-08 2009-07-08 Notch1 receptor binding agents and methods of use thereof
US13/003,013 US8435513B2 (en) 2008-07-08 2009-07-08 NOTCH1 receptor antibodies and methods of treatment
DK09794822.8T DK2307459T3 (da) 2008-07-08 2009-07-08 Notch1-receptorbindende midler og fremgangsmåder til anvendelse deraf
ES09794822.8T ES2531541T3 (es) 2008-07-08 2009-07-08 Agentes de unión del receptor Notch1 y procedimientos de uso de los mismos
MEP-2015-20A ME02069B (me) 2008-07-08 2009-07-08 Vezujuci agensi notch1 receptora i postupci njihove primene
UAA201101442A UA101672C2 (uk) 2008-07-08 2009-08-07 Антитіло, що зв'язується з рецептором notch1, і його застосування
IL210222A IL210222A (en) 2008-07-08 2010-12-23 Antibodies associated with 1notch receptor and their methods of use
MA33483A MA32448B1 (fr) 2008-07-08 2011-01-03 Agents de liaison de recepteur notch1 et procedes d'utilisation
ZA2011/00029A ZA201100029B (en) 2008-07-08 2011-01-03 Notch1 receptor binding agents and methods of use thereof
HK11105234.2A HK1151296A1 (en) 2008-07-08 2011-05-26 Notch1 receptor binding agents and methods of use thereof notch1
US13/797,374 US9132189B2 (en) 2008-07-08 2013-03-12 Notch1 binding agents and methods of use thereof
US13/801,613 US8945874B2 (en) 2008-07-08 2013-03-13 Polynucleotides encoding NOTCH1 receptor antibodies
US13/826,284 US8945547B2 (en) 2008-07-08 2013-03-14 Notch1 receptor antibodies and methods of treatment
US14/577,484 US9499613B2 (en) 2008-07-08 2014-12-19 Notch1 receptor binding agents and methods of use thereof
SM201500047T SMT201500047B (it) 2008-07-08 2015-03-02 Agenti leganti il recettore notch1 e loro metodi d'uso
HRP20150256AT HRP20150256T1 (hr) 2008-07-08 2015-03-06 Djelatna sredstva za vezanje notch1-receptora i postupci njihove uporabe
US15/291,334 US20170183405A1 (en) 2008-07-08 2016-10-12 Notch1 receptor binding agents and methods of use thereof

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US7909508P 2008-07-08 2008-07-08
US61/079,095 2008-07-08
US11270108P 2008-11-07 2008-11-07
US11269908P 2008-11-07 2008-11-07
US61/112,699 2008-11-07
US61/112,701 2008-11-07

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US13/003,013 A-371-Of-International US8435513B2 (en) 2008-07-08 2009-07-08 NOTCH1 receptor antibodies and methods of treatment
US13/005,966 Continuation-In-Part US8834875B2 (en) 2008-07-08 2011-01-13 Notch1 binding agents and methods of use thereof
US13/801,613 Continuation US8945874B2 (en) 2008-07-08 2013-03-13 Polynucleotides encoding NOTCH1 receptor antibodies
US13/826,284 Continuation US8945547B2 (en) 2008-07-08 2013-03-14 Notch1 receptor antibodies and methods of treatment

Publications (2)

Publication Number Publication Date
WO2010005567A2 WO2010005567A2 (fr) 2010-01-14
WO2010005567A3 true WO2010005567A3 (fr) 2010-05-27

Family

ID=41507637

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2009/003995 WO2010005567A2 (fr) 2008-07-08 2009-07-08 Agents de liaison de récepteur notch1 et procédés d'utilisation
PCT/US2009/003994 WO2010005566A2 (fr) 2008-07-08 2009-07-08 Agents de liaison de notch et antagonistes de notch ainsi que procédés d'utilisation correspondants

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2009/003994 WO2010005566A2 (fr) 2008-07-08 2009-07-08 Agents de liaison de notch et antagonistes de notch ainsi que procédés d'utilisation correspondants

Country Status (32)

Country Link
US (11) US8226943B2 (fr)
EP (4) EP2899211A1 (fr)
JP (2) JP5560271B2 (fr)
KR (2) KR101682490B1 (fr)
CN (3) CN102112490B (fr)
AU (2) AU2009269095B2 (fr)
BR (2) BRPI0914004A2 (fr)
CA (2) CA2729306C (fr)
CO (2) CO6390041A2 (fr)
CR (1) CR20110069A (fr)
CY (2) CY1116195T1 (fr)
DK (2) DK2307051T3 (fr)
DO (2) DOP2011000002A (fr)
EA (2) EA201170157A1 (fr)
ES (2) ES2531541T3 (fr)
HK (2) HK1151218A1 (fr)
HR (2) HRP20150256T1 (fr)
IL (2) IL210222A (fr)
MA (2) MA32448B1 (fr)
ME (2) ME02069B (fr)
MX (2) MX2011000236A (fr)
MY (2) MY159815A (fr)
NZ (2) NZ590131A (fr)
PL (2) PL2307459T3 (fr)
PT (2) PT2307459E (fr)
RS (2) RS53750B1 (fr)
SG (2) SG192467A1 (fr)
SI (2) SI2307051T1 (fr)
SM (2) SMT201500047B (fr)
UA (1) UA101672C2 (fr)
WO (2) WO2010005567A2 (fr)
ZA (2) ZA201009280B (fr)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
WO2007136856A2 (fr) * 2006-05-19 2007-11-29 The Johns Hopkins University Heyl utilisé en tant que cible thérapeutique et en tant que marqueur diagnostique d'une néoplasie et utilisations correspondantes
US7919092B2 (en) 2006-06-13 2011-04-05 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
NZ577274A (en) 2006-12-18 2012-10-26 Genentech Inc Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
AU2008209482B2 (en) 2007-01-24 2014-05-01 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
US8226943B2 (en) 2008-07-08 2012-07-24 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
AU2009298569A1 (en) * 2008-10-01 2010-04-08 Genentech, Inc. Anti-Notch2 antibodies and methods of use
SG176731A1 (en) 2009-06-18 2012-01-30 Pfizer Anti notch-1 antibodies
JP6025563B2 (ja) * 2009-09-30 2016-11-16 ジェネンテック， インコーポレイテッド Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性癌の治療
EP2488204B1 (fr) 2009-10-16 2016-04-06 Oncomed Pharmaceuticals, Inc. Combinaison thérapeutique et utilisation d'anticorps antagonistes de dll4 et d'agents anti-hypertenseurs
ES2561102T3 (es) 2010-01-13 2016-02-24 Oncomed Pharmaceuticals, Inc. Agentes de unión a Notch1 y procedimientos de uso de los mismos
AU2011223883B2 (en) 2010-03-01 2015-10-08 Cavion, Inc. Cancer diagnosis and imaging
RU2636461C2 (ru) * 2010-05-03 2017-11-23 Дженентек, Инк. Композиции и способы для диагностики и лечения опухоли
PH12013501255A1 (en) 2010-12-15 2013-08-05 Wyeth Llc Anti-notch1 antibodies
US20130058947A1 (en) * 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
EP2755674A4 (fr) * 2011-09-12 2015-04-08 Tau Therapeutics Llc Antagonistes des produits du groupe unigene hs.459642 pour inhiber la prolifération, le développement ou la différenciation des cellules souches comprenant des cellules souches cancéreuses
SMT201900075T1 (it) 2011-09-23 2019-02-28 Oncomed Pharm Inc Agenti leganti vegf/dll4 e relativi usi
TW201329105A (zh) * 2011-10-04 2013-07-16 Thr Trustees Of Columbia University In The City Of New York 人類ｎｏｔｃｈ１引誘物
US20130089562A1 (en) 2011-10-05 2013-04-11 Genenthech, Inc. Methods of treating liver conditions using notch2 antagonists
RU2014122048A (ru) * 2011-11-16 2015-12-27 Онкомед Фармасьютикалс, Инк. Мутации рецептора notch человека и их применение
KR101535219B1 (ko) * 2011-11-18 2015-07-09 한국생명공학연구원 Ｎｏｔｃｈ３에 대한 인간 단일클론항체
US9534058B2 (en) 2012-02-08 2017-01-03 Abbvie Stemcentrx Llc Anti-CD324 monoclonal antibodies and uses thereof
US20130323266A1 (en) * 2012-05-16 2013-12-05 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with notch2/3 antibodies
RU2666990C2 (ru) 2012-08-13 2018-09-13 Дженентек, Инк. Антитела к jagged и способы их применения
CA2884309A1 (fr) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methodes et compositions pour la regeneration des cellules de cheveux et/ou des cellules de soutien a partir de cellules cochleaires differenciees ou de cellules utriculaires differenciees par modulation de l'activite de notch et de c-myc
WO2014047426A1 (fr) * 2012-09-21 2014-03-27 Oncomed Pharmaceuticals, Inc. Méthodes de traitement de malignités hématologiques par des anticorps dirigés contre notch1
US9326999B2 (en) * 2012-10-09 2016-05-03 Sanbio, Inc. Methods and compositions for treatment of retinal degeneration
WO2014071018A1 (fr) 2012-10-31 2014-05-08 Oncomed Pharmaceuticals, Inc. Méthodes et surveillance d'un traitement par un antagoniste de dll4
WO2014072897A1 (fr) * 2012-11-07 2014-05-15 Pfizer Inc. Anticorps anti-notch3 et conjugués anticorps-médicament
ES2737649T3 (es) * 2012-12-19 2020-01-15 Aveo Pharmaceuticals Inc Anticuerpos anti-Notch3
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
JP2016517266A (ja) * 2013-02-18 2016-06-16 ユニバーシティー ヘルス ネットワーク 多能性幹細胞から肝細胞及び胆管細胞を作製する方法
US9944700B2 (en) 2013-03-13 2018-04-17 Novartis Ag Notch2 binding molecules for treating respiratory diseases
CN105246916A (zh) * 2013-03-14 2016-01-13 诺华股份有限公司 针对notch 3的抗体
TW201511770A (zh) 2013-03-15 2015-04-01 Genentech Inc 診斷及治療肝癌之組合物及方法
AU2014233736A1 (en) * 2013-03-15 2015-08-27 Oncomed Pharmaceuticals, Inc. Methods of treating pancreatic cancer
HUE039940T2 (hu) 2014-02-12 2019-02-28 Hoffmann La Roche Anti-Jagged1 antitestek és alkalmazási eljárások
WO2015153997A2 (fr) * 2014-04-04 2015-10-08 Oncomed Pharmaceuticals, Inc. Anticorps anti-notch 3 et leurs utilisations
EP3166627A1 (fr) 2014-07-11 2017-05-17 Genentech, Inc. Inhibition de la voie de signalisation notch
GB201416832D0 (en) * 2014-09-24 2014-11-05 Glaxosmithkline Plc Methods of treatment
WO2016069906A1 (fr) 2014-10-29 2016-05-06 Massachusetts Eye And Ear Infirmary Administration efficace de molécules thérapeutiques en direction de cellules de l'oreille interne
MX382902B (es) * 2014-10-31 2025-03-13 Oncomed Pharm Inc Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
CN105986001B (zh) * 2015-02-12 2019-12-03 上海交通大学 一种基于膜结合蛋白和荧光互补的高通量猎物拮抗剂筛选方法
US10590182B2 (en) * 2015-02-24 2020-03-17 The Regents Of The University Of California Binding-triggered transcriptional switches and methods of use thereof
TWI609687B (zh) * 2015-04-14 2018-01-01 美國禮來大藥廠 平滑肌肉瘤之標靶性治療
JP6726174B2 (ja) * 2015-04-16 2020-07-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗ヒトＮｏｔｃｈ４抗体
ES2968074T3 (es) 2015-09-23 2024-05-07 Mereo Biopharma 5 Inc Anticuerpo bi-específico anti-VEGF/DLL4 para su uso en el tratamiento del cáncer de ovario resistente al platino
CN105585636B (zh) * 2015-11-24 2020-03-03 南方医科大学 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用
EA201892096A1 (ru) 2016-03-16 2019-08-30 Эйбоум Корпорейшн Нейтрализующие моноклональные антитела к il-25 и их применение
US11142573B2 (en) 2016-04-29 2021-10-12 Aveo Pharmaceuticals, Inc. Anti-Notch3 antibody
WO2017193059A1 (fr) 2016-05-06 2017-11-09 The Regents Of The University Of California Systèmes et procédés de ciblage de cellules cancéreuses
US11026996B2 (en) * 2016-05-25 2021-06-08 The Trustees Of Columbia University In The City Of New York Human Notch1 based fusion proteins as decoy inhibitors of jagged-notch signaling and DLL-notch signaling
KR102637610B1 (ko) 2016-08-23 2024-02-19 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 단백질용해 절단가능한 키메라 폴리펩타이드 및 이의 사용 방법
KR20230111264A (ko) * 2016-11-07 2023-07-25 더 위스타 인스티튜트 오브 아나토미 앤드 바이올로지 라임병에 사용하기 위한 dna 항체 작제물
WO2018183216A1 (fr) 2017-03-27 2018-10-04 The Schepens Eye Research Institute, Inc. Compositions d'agonistes de notch3 et méthodes de traitement des maladies des petits vaisseaux
US20200103419A1 (en) 2017-03-27 2020-04-02 The Schepens Eye Research Institute, Inc. Blood biomarkers and diagnostic methods for small vessel diseases
US11325957B2 (en) * 2017-06-19 2022-05-10 Cell Design Labs, Inc. Methods and compositions for reducing the immunogenicity of chimeric notch receptors
CN107557343B (zh) * 2017-08-09 2020-09-25 苏州大学附属儿童医院 抗人dll4单克隆抗体3f9
EP3743057A4 (fr) 2018-01-26 2021-11-17 Massachusetts Eye & Ear Infirmary Traitement de la perte auditive
KR20210008840A (ko) * 2018-04-10 2021-01-25 스티흐팅 산퀸 불드포르지닝 키메라 노치 수용체
WO2020016855A1 (fr) * 2018-07-20 2020-01-23 The Hong Kong Polytechnic University Peptides pour l'inhibition spécifique de la voie de signalisation jag1-notch1
EP3877399A4 (fr) * 2018-11-06 2022-10-19 Alsatech, Inc. Thérapie génique de maladies neurodégénératives à base de cellules
CN111334575A (zh) * 2020-02-18 2020-06-26 至本医疗科技（上海）有限公司 Notch家族基因变异在预测实体瘤患者对免疫检查点抑制剂疗法敏感性中的应用
BR112023000839A2 (pt) 2020-07-17 2023-02-07 Genentech Inc Anticorpos isolados, ácido nucleico isolado, célula hospedeira, métodos para produzir um anticorpo que se liga a notch2 humano, para tratar um indivíduo com uma doença pulmonar muco-obstrutiva e para reduzir o número de células secretoras em um indivíduo, composição farmacêutica, anticorpo, anticorpo para uso e uso do anticorpo
CN112625125B (zh) * 2021-01-18 2021-12-14 中国人民解放军军事科学院军事医学研究院 一株中和新型冠状病毒感染的单抗
US12245355B2 (en) 2021-02-19 2025-03-04 Mevion Medical Systems, Inc. Gantry for a particle therapy system
WO2022272283A1 (fr) * 2021-06-24 2022-12-29 H. Lee Moffitt Cancer Center And Research Institute Inc. Cellules t à double récepteur antigénique chimérique egfr-muc1
WO2023141445A1 (fr) 2022-01-19 2023-07-27 Genentech, Inc. Anticorps et conjugués anti-notch2, et méthodes d'utilisation
CN118344474B (zh) * 2024-05-28 2024-11-15 中国农业科学院兰州兽医研究所(中国动物卫生与流行病学中心兰州分中心) 口蹄疫病毒O型、A型和Asia1型广谱中和性猪源单克隆抗体及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080118520A1 (en) * 2006-10-19 2008-05-22 Kang Li Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases
US20080131434A1 (en) * 2006-06-13 2008-06-05 Lewicki John A Compositions and methods for diagnosing and treating cancer

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US6344321B1 (en) 1990-06-11 2002-02-05 Gilead Sciences, Inc. Nucleic acid ligands which bind to hepatocyte growth factor/scatter factor (HGF/SF) or its receptor c-met
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5840867A (en) 1991-02-21 1998-11-24 Gilead Sciences, Inc. Aptamer analogs specific for biomolecules
DE122009000019I1 (de) 1991-04-25 2009-07-16 Chugai Seiyaku K K 5 1 Rekombinierte humane antikörper gegen den humanen interleukin-6 rezeptor
IE20030749A1 (en) * 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
IL101728A (en) 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US20050112121A1 (en) * 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5756291A (en) 1992-08-21 1998-05-26 Gilead Sciences, Inc. Aptamers specific for biomolecules and methods of making
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
AU5752696A (en) 1995-05-18 1996-11-29 Regents Of The University Of Michigan, The Dna binding antibodies
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
US6696248B1 (en) 1995-08-18 2004-02-24 Morphosys Ag Protein/(poly)peptide libraries
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
JP2000515364A (ja) 1996-03-30 2000-11-21 サイエンス パーク ラフ ソチエタ ペル アツィオニ 標識した活性化腫瘍特異的ｔ細胞の生産方法および腫瘍療法におけるそれらの使用
WO1997045143A1 (fr) 1996-05-31 1997-12-04 The National American Red Cross Procedes et compositions therapeutiques et diagnostiques obtenues a partir de proteines jagged/notch et d'acides nucleiques
FR2751986B1 (fr) * 1996-08-01 1998-12-31 Inst Nat Sante Rech Med Gene implique dans le cadasil, methode de diagnostic et application therapeutique
CN1160371C (zh) 1996-11-07 2004-08-04 洛伦蒂斯有限公司 Notch蛋白及其配体
IL132560A0 (en) 1997-05-02 2001-03-19 Genentech Inc A method for making multispecific antibodies having heteromultimeric and common components
US6379925B1 (en) * 1997-06-18 2002-04-30 The Trustees Of Columbia University In The City Of New York Angiogenic modulation by notch signal transduction
AU8162898A (en) 1997-06-18 1999-01-04 Trustees Of Columbia University In The City Of New York, The Angiogenic modulation by notch signal transduction
US6692919B1 (en) 1997-07-23 2004-02-17 Yale University Activated forms of notch and methods based thereon
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
US7361336B1 (en) * 1997-09-18 2008-04-22 Ivan Bergstein Methods of cancer therapy targeted against a cancer stem line
AU768269B2 (en) 1998-10-02 2003-12-04 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Apoptosis inducing agents and methods
US20030054360A1 (en) 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
US20030003572A1 (en) 1999-03-05 2003-01-02 David J. Anderson Isolation and enrichment of neural stem cells from uncultured tissue based on cell-surface marker expression
US20020010320A1 (en) 1999-04-05 2002-01-24 James W. Fett Chemeric and humanized antibodies to angiogenin
ES2353268T3 (es) 1999-07-02 2011-02-28 Morphosys Ag Generacion de elementos de union especifica que se unen a (poli)peptidos codificados por fragmentos de adn genomico o est.
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US20030031670A1 (en) 1999-11-08 2003-02-13 Jack R. Wands Diagnosis and treatment of malignant neoplasms
DE10031380A1 (de) 2000-06-28 2002-01-10 Merck Patent Gmbh Verfahren zur Übertragung von Alkyliden-Gruppen auf organischen Verbindungen
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US20080194022A1 (en) 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
WO2002018544A2 (fr) 2000-08-31 2002-03-07 Loyola University Chicago Procedes et reactifs permettant la formation d'une barriere epitheliale et traitement d'affections cutanees malignes et benignes par modulation de la voie notch
US6689744B2 (en) 2000-09-22 2004-02-10 Genentech, Inc. Notch receptor agonists and uses
WO2002026932A2 (fr) 2000-09-26 2002-04-04 Duke University Aptameres d'arn et procede d'identification desdits aptameres
EP1322761A4 (fr) 2000-10-02 2005-03-23 Korea Res Inst Of Bioscience Anticorps humanise dirige contre l'antigene s de surface du virus de l'hepatite b et procede de preparation de ce dernier
CA2445168A1 (fr) 2001-04-24 2002-10-31 Bayer Corporation Anticorps timp-1 humains
US7356224B2 (en) * 2001-07-03 2008-04-08 Brown University Research Foundation Method and apparatus for detecting multiple optical wave lengths
JP2005526701A (ja) 2001-11-14 2005-09-08 ロランティス リミテッド 内科療法
CA2469204A1 (fr) 2001-12-07 2003-06-19 Regents Of The University Of Michigan Identification et caracterisation prospectives des cellules souches cancereuses du sein
GB0201674D0 (en) 2002-01-25 2002-03-13 Lorantis Ltd Medical treatment
CA2476309A1 (fr) 2002-02-15 2003-08-28 Somalogic, Inc. Methodes et reactifs destines a la detection d'une liaison de cibles par des ligands d'acides nucleiques
EP1534331B1 (fr) 2002-06-21 2014-10-29 Johns Hopkins University School of Medicine Marqueurs de l'endothelium tumoral associe a une membrane
DE10228103A1 (de) 2002-06-24 2004-01-15 Bayer Cropscience Ag Fungizide Wirkstoffkombinationen
EP1578367A4 (fr) 2002-11-01 2012-05-02 Genentech Inc Compositions et methodes pour le traitement de maladies liees au systeme immunitaire
US20050124565A1 (en) 2002-11-21 2005-06-09 Diener John L. Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
CA2508715A1 (fr) 2002-12-06 2004-06-24 Singapore General Hospital Pte Ltd. Substances et procedes associes au traitement de blessures et de maladies du systeme nerveux central
JP2007525167A (ja) 2003-04-01 2007-09-06 ジェンザイム・コーポレーション 乳房内皮細胞発現パターン
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US7563748B2 (en) 2003-06-23 2009-07-21 Cognis Ip Management Gmbh Alcohol alkoxylate carriers for pesticide active ingredients
US7329742B2 (en) 2003-09-04 2008-02-12 The Regents Of The University Of California Aptamers and methods for their in vitro selection and uses thereof
GB0321805D0 (en) 2003-09-18 2003-10-15 Univ Wales Medicine Human tumour growth patterns
US7282203B2 (en) 2003-11-26 2007-10-16 Health Research, Inc. Use of NOTCH pathway interfering agents for treatment of plasma cell disorders
JP2007526455A (ja) 2004-02-03 2007-09-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法
FR2867784B1 (fr) 2004-03-17 2006-06-09 Commissariat Energie Atomique Aptameres selectionnes a partir de cellules vivantes tumorales et leurs applications
WO2005090981A2 (fr) * 2004-03-24 2005-09-29 Technion Research & Development Foundation Ltd. Recepteurs artificiels
US20050239134A1 (en) 2004-04-21 2005-10-27 Board Of Regents, The University Of Texas System Combinatorial selection of phosphorothioate single-stranded DNA aptamers for TGF-beta-1 protein
WO2005111072A2 (fr) * 2004-04-29 2005-11-24 The Trustees Of Columbia University In The City Of New York Protéines hybrides de notch et leurs utilisations
RU2346996C2 (ru) 2004-06-29 2009-02-20 ЮРОПИЭН НИКЕЛЬ ПиЭлСи Усовершенствованное выщелачивание основных металлов
US20070077245A1 (en) 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling
GB0421838D0 (en) 2004-09-30 2004-11-03 Congenia S R L Cancer markers
WO2006053063A2 (fr) 2004-11-05 2006-05-18 The Regents Of The University Of California Dosage de notch-1 utilise dans la detection de maladies neurodegeneratives
NZ555216A (en) * 2004-11-10 2010-05-28 Hubrecht Lab Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation
CA3218940A1 (fr) 2004-11-12 2006-05-18 Cambridge University Technical Services Ltd. Procedes et moyens lies aux cellules souches cancereuses
EP1871911A2 (fr) 2005-04-07 2008-01-02 Chiron Corporation Génes liés au cancer (prlr)
MX2007016203A (es) 2005-06-29 2008-03-10 Compumedics Ltd Ensamble de sensor con puente conductivo.
EP1945754B1 (fr) 2005-10-31 2014-07-23 The Regents Of The University Of Michigan Compositions et méthodes pour traiter et diagnostiquer un cancer
US20090305310A1 (en) 2005-11-22 2009-12-10 University Of Vermont And State Agricultural College Methods for Determining Notch Signaling and Uses Thereof
AU2006326417B2 (en) 2005-12-16 2012-05-24 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with Dll4 antagonists
WO2007075914A2 (fr) 2005-12-22 2007-07-05 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps monoclonaux utilises contre des orthopoxvirus
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
US20080241150A1 (en) 2006-05-15 2008-10-02 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human NOTCH1 and 2 and isolated LNR domains from human NOTCH1
CA2654304A1 (fr) 2006-06-06 2007-12-13 Genentech, Inc. Compositions et procedes destines a moduler le developpement vasculaire
MX2008015541A (es) 2006-06-06 2008-12-18 Genentech Inc Anticuerpos anti-dll4 y metodos que los usan.
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
WO2008050525A1 (fr) 2006-09-29 2008-05-02 Konica Minolta Opto, Inc. Film retardateur
JP5535633B2 (ja) * 2006-09-29 2014-07-02 オンコメッド ファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
CA2666179A1 (fr) 2006-10-19 2008-11-13 Genentech, Inc. Nouveaux anticorps anti-notch3 et leur utilisation dans la detection et le diagnostic d'une maladie
US7700113B2 (en) * 2006-10-19 2010-04-20 Maine Medical Research Institute, A Division Of Maine Medical Center Inhibiting breast cancer cell growth by administering an intracellular domain of NOTCH2
US20100068688A1 (en) 2006-11-06 2010-03-18 Howard Shapiro Management of teaching processes for individualized instruction in a multistudent environment
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
NZ577274A (en) * 2006-12-18 2012-10-26 Genentech Inc Antagonist anti-notch3 antibodies and their use in the prevention and treatment of notch3-related diseases
WO2008079326A2 (fr) 2006-12-20 2008-07-03 Vasgene Therapeutics, Inc. Procédés d'utilisation et d'identification de modulateurs de dll4
AU2008209482B2 (en) 2007-01-24 2014-05-01 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US20100119526A1 (en) 2007-01-26 2010-05-13 Bioinvent International Ab DLL4 Signaling Inhibitors and Uses Thereof
US20090208491A1 (en) * 2007-02-14 2009-08-20 Austin Gurney Compositions and Methods for Diagnosing and Treating Cancer
WO2008109075A2 (fr) * 2007-03-05 2008-09-12 Bristol-Myers Squibb Company Biomarqueurs et procédés pour déterminer une sensibilité à des antagonistes de ctla-4
US20100062012A1 (en) 2007-03-05 2010-03-11 Ioannides Constantin G Negative Genetic Regulation of Cancer Cell Renewal in Synergy with Notch- or Numb-Specific Immunotherapy
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
CN103819560B (zh) * 2007-07-16 2017-01-04 健泰科生物技术公司 抗cd79b抗体和免疫偶联物及使用方法
KR20100076947A (ko) 2007-08-23 2010-07-06 더 트러스티스 오브 컬럼비아 유니버시티 인 더 시티 오브 뉴욕 인간화 노치 융합 단백질 조성물 및 치료방법
US20110166028A1 (en) 2007-08-28 2011-07-07 Donald Bergstrom Methods for predicting treatment response based on the expression profiles of biomarker genes in notch mediated cancers
WO2009036167A1 (fr) 2007-09-14 2009-03-19 Vanderbilt University Ciblage d'une fonction de récepteurs notch3 pour une thérapie du cancer
US8377886B2 (en) 2007-09-14 2013-02-19 Albert Einstein College Of Medicine Of Yeshiva University Use of gamma secretase inhibitors and notch pathway inhibitors for treatment and prevention of renal disease
US20120082659A1 (en) 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
US8119366B2 (en) 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
EP2260058A2 (fr) 2008-04-07 2010-12-15 Ablynx N.V. Séquences d acides aminés dirigées contre les voies notch et leurs utilisations
WO2010000020A1 (fr) 2008-06-30 2010-01-07 Cathrx Ltd Cathéter
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
US8226943B2 (en) 2008-07-08 2012-07-24 Oncomed Pharmaceuticals, Inc. Antibodies to notch receptors
AU2009298569A1 (en) 2008-10-01 2010-04-08 Genentech, Inc. Anti-Notch2 antibodies and methods of use
JP2012520325A (ja) 2009-03-13 2012-09-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア プレバイオティックオリゴ糖
JP6025563B2 (ja) 2009-09-30 2016-11-16 ジェネンテック， インコーポレイテッド Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性癌の治療
DE102009047243A1 (de) 2009-11-27 2011-06-01 Orgentec Diagnostika Gmbh Monospezifische Polypeptidreagenzien
ES2561102T3 (es) 2010-01-13 2016-02-24 Oncomed Pharmaceuticals, Inc. Agentes de unión a Notch1 y procedimientos de uso de los mismos
SG10201503736XA (en) 2010-02-12 2015-06-29 Oncomed Pharm Inc Methods for identifying and isolating cells expressing a polypeptide
JP5450221B2 (ja) 2010-04-14 2014-03-26 株式会社神戸製鋼所 高電流密度ガスシールドアーク溶接方法
MX355418B (es) 2010-05-04 2018-04-18 Five Prime Therapeutics Inc Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
WO2012003472A1 (fr) 2010-07-02 2012-01-05 Aveo Pharmaceuticals, Inc. Anticorps anti-notch1
SI2683406T1 (sl) 2011-03-11 2019-10-30 Beth Israel Deconess Medical Center Inc Protitelesa ANTI-CD40 in njihova uporaba
RU2014122048A (ru) 2011-11-16 2015-12-27 Онкомед Фармасьютикалс, Инк. Мутации рецептора notch человека и их применение
US20130323266A1 (en) 2012-05-16 2013-12-05 Oncomed Pharmaceuticals, Inc. Methods for treating cancer with notch2/3 antibodies
US11291644B2 (en) 2012-09-04 2022-04-05 Eleison Pharmaceuticals, Llc Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
WO2014047426A1 (fr) 2012-09-21 2014-03-27 Oncomed Pharmaceuticals, Inc. Méthodes de traitement de malignités hématologiques par des anticorps dirigés contre notch1
WO2014072897A1 (fr) 2012-11-07 2014-05-15 Pfizer Inc. Anticorps anti-notch3 et conjugués anticorps-médicament
AU2014233736A1 (en) 2013-03-15 2015-08-27 Oncomed Pharmaceuticals, Inc. Methods of treating pancreatic cancer
CA2941733A1 (fr) 2014-03-07 2015-09-11 Oncomed Pharmaceuticals, Inc. Procedes de traitement du cancer au moyen d'anticorps anti-notch1
WO2015153997A2 (fr) 2014-04-04 2015-10-08 Oncomed Pharmaceuticals, Inc. Anticorps anti-notch 3 et leurs utilisations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080131434A1 (en) * 2006-06-13 2008-06-05 Lewicki John A Compositions and methods for diagnosing and treating cancer
US20080118520A1 (en) * 2006-10-19 2008-05-22 Kang Li Anti-notch3 agonist antibodies and their use in the treatment of notch3-related diseases

Also Published As

Publication number Publication date
DK2307051T3 (en) 2015-04-20
CA2729306A1 (fr) 2010-01-14
AU2009269096B2 (en) 2016-05-12
EA201170157A1 (ru) 2011-08-30
MY155603A (en) 2015-11-13
SMT201500047B (it) 2015-05-05
MX2011000233A (es) 2011-05-19
KR20110028621A (ko) 2011-03-21
AU2009269096A1 (en) 2010-01-14
US8945873B2 (en) 2015-02-03
CY1116195T1 (el) 2017-02-08
AU2016216568A1 (en) 2016-09-01
MX2011000236A (es) 2011-02-24
ME02069B (me) 2015-05-20
CR20110069A (es) 2011-07-11
KR101640099B1 (ko) 2016-07-15
US20140011271A1 (en) 2014-01-09
EP2307051A4 (fr) 2012-07-18
SG192467A1 (en) 2013-08-30
SMT201500120B (it) 2015-07-09
MA32448B1 (fr) 2011-07-03
CO6612253A2 (es) 2013-02-01
CN102316897A (zh) 2012-01-11
JP5560270B2 (ja) 2014-07-23
JP2012501626A (ja) 2012-01-26
JP5560271B2 (ja) 2014-07-23
US20150166963A1 (en) 2015-06-18
RS53750B1 (en) 2015-06-30
IL210222A (en) 2016-05-31
CO6390041A2 (es) 2012-02-29
DOP2011000004A (es) 2011-04-15
ES2531541T3 (es) 2015-03-17
CY1116230T1 (el) 2017-02-08
PT2307051E (pt) 2015-05-21
US8226943B2 (en) 2012-07-24
MY159815A (en) 2017-02-15
PL2307459T3 (pl) 2015-05-29
US20130296536A1 (en) 2013-11-07
US20170198031A1 (en) 2017-07-13
WO2010005566A2 (fr) 2010-01-14
MA32449B1 (fr) 2011-07-03
PT2307459E (pt) 2015-03-11
EP2307051A2 (fr) 2011-04-13
ES2535614T3 (es) 2015-05-13
CA2729306C (fr) 2015-08-18
SI2307051T1 (sl) 2015-04-30
HK1151218A1 (en) 2012-01-27
WO2010005566A3 (fr) 2010-09-16
UA101672C2 (uk) 2013-04-25
NZ590127A (en) 2012-11-30
CN102112490A (zh) 2011-06-29
US20130260455A1 (en) 2013-10-03
HRP20150443T1 (hr) 2015-05-22
US20110311552A1 (en) 2011-12-22
EA026109B1 (ru) 2017-03-31
DK2307459T3 (da) 2015-02-09
AU2009269095A1 (en) 2010-01-14
CA2729602A1 (fr) 2010-01-14
ZA201100029B (en) 2012-03-28
HRP20150256T1 (hr) 2015-04-10
WO2010005567A2 (fr) 2010-01-14
RS53924B1 (en) 2015-08-31
SG192468A1 (en) 2013-08-30
IL210221A0 (en) 2011-03-31
EP2307459B1 (fr) 2015-01-07
CN102316897B (zh) 2014-11-05
US8980260B2 (en) 2015-03-17
HK1151296A1 (en) 2012-01-27
BRPI0914007A2 (pt) 2015-11-17
US20120288496A1 (en) 2012-11-15
PL2307051T3 (pl) 2015-07-31
US9505832B2 (en) 2016-11-29
ZA201009280B (en) 2012-04-25
IL210221A (en) 2014-02-27
US8945547B2 (en) 2015-02-03
EA201170158A1 (ru) 2011-08-30
JP2012501625A (ja) 2012-01-26
CN104402998A (zh) 2015-03-11
IL210222A0 (en) 2011-03-31
ME02148B (me) 2015-10-20
US9499613B2 (en) 2016-11-22
AU2009269095B2 (en) 2016-05-19
US20130280277A1 (en) 2013-10-24
DOP2011000002A (es) 2011-04-15
SI2307459T1 (sl) 2015-04-30
US8945874B2 (en) 2015-02-03
EP2307459A2 (fr) 2011-04-13
EP2307459A4 (fr) 2012-07-18
NZ590131A (en) 2012-10-26
EP2307051B1 (fr) 2015-02-11
US8435513B2 (en) 2013-05-07
US20100111958A1 (en) 2010-05-06
KR20110031315A (ko) 2011-03-25
EP2924051A1 (fr) 2015-09-30
US8425903B2 (en) 2013-04-23
KR101682490B1 (ko) 2016-12-05
EP2899211A1 (fr) 2015-07-29
BRPI0914004A2 (pt) 2015-11-17
CN102112490B (zh) 2014-10-22
US20150197563A1 (en) 2015-07-16
US20170183405A1 (en) 2017-06-29

Similar Documents

Publication Publication Date Title
WO2010005567A3 (fr) Agents de liaison de récepteur notch1 et procédés d'utilisation
WO2007145840A3 (fr) Compositions et procédés de diagnostic et de traitement du cancer
WO2007133250A3 (fr) Compositions et procédés de diagnostic et de traitement du cancer
EA201170136A1 (ru) Мультимасштабный метод конечных объемов для моделирования резервуара
WO2010019702A3 (fr) Agents de liaison à ddr1 et leurs méthodes d'utilisation
EA200970335A1 (ru) Композиции и способы для диагностики и лечения рака
WO2010059969A3 (fr) Thérapie antiangiogenèse pour le traitement du cancer du sein
WO2011063237A3 (fr) Agents de liaison au jagged et utilisations associées
WO2011088215A3 (fr) Agents de liaison notch1 et leurs procédés d'utilisation
WO2009020933A3 (fr) Utilisation thérapeutique anticorps de récepteur anti-tweak
WO2010017515A3 (fr) Marqueurs spécifiques du cancer du sein et procédés d’utilisation
WO2008091641A3 (fr) Compositions et procédés utilisés pour le diagnostic et le traitement du cancer
WO2014205555A8 (fr) Procédés et utilisations pour diagnostiquer et traiter le cancer de la prostate
WO2010129033A3 (fr) Anticorps modifiés pour immunothérapie passive
WO2014012007A3 (fr) Agents de liaison des protéines rspo3 et leurs utilisations
PH12014501119A1 (en) Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
WO2009149485A3 (fr) Composés destinés au traitement des amyloïdoses
WO2009149106A3 (fr) Microparticules pour le traitement d'une maladie
WO2010086828A3 (fr) Anticorps monoclonaux agonistes anti-trkb
WO2008003656A3 (fr) Produits de la transcription spécifiques de la prostate et leur utilisation pour des thérapeutiques et des diagnostics du cancer de la prostate
WO2012048170A3 (fr) Animaux humanisés par ingénierie tissulaire et leurs utilisations
WO2010054377A3 (fr) Anticorps entièrement humains dirigés contre la n-cadhérine
WO2010054397A3 (fr) N-cadhérine en tant que cible pour le diagnostic et le traitement du cancer
WO2008070090A3 (fr) Compositions et procédés pour diagnostiquer et traiter un cancer
WO2009091230A3 (fr) Marqueur protéique pour la surveillance, le diagnostic et le dépistage du cancer du sein, et méthode de surveillance, de diagnostic et de dépistage de cancer du sein faisant appel audit marqueur

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980126471.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09794822

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2011517417

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009269096

Country of ref document: AU

Ref document number: 590127

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 210222

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2729602

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 4953/KOLNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2011010030

Country of ref document: EG

Ref document number: 12011500033

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: MX/A/2011/000233

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 20117000736

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009269096

Country of ref document: AU

Date of ref document: 20090708

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: DZP2011000108

Country of ref document: DZ

WWE Wipo information: entry into national phase

Ref document number: 2009794822

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201170158

Country of ref document: EA

Ref document number: CR2011-000069

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: A201101442

Country of ref document: UA

Ref document number: 11014588

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 13003013

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: P-2015/0120

Country of ref document: RS

ENP Entry into the national phase

Ref document number: PI0914004

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101230

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载